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Introduction: Factors predictive of response to immunotherapy are needed to select appropriate patients. As morphometric analysis can be an
objective surrogate for underlying physiology, we explored the possibility that morphomics may predict response among stage IV melanoma
patients treated with ipilimumab.
Methods:We identified stage IV melanoma patients treated with ipilimumab who had an appropriate CT scan within a 6 month window. Using
semi-automated algorithms, we acquired several morphomic measurements. Toxicity and response rate compared by quartile using Fisher’s exact
test or chi-square, while survival after initiation of ipilimumab was compared by quartile using the log-rank test.
Results:While there was a significant correlation between toxicity and response (P< .003), morphomics failed to predict either severity of toxicity
or specific side effects. Psoas density was significantly associated with response rate, both excluding stable disease (36.4% vs 9.1%, P¼ .054), and
including stable disease (54.5% versus 18.2%, P¼ 0.045). Survival after initiation of ipilimumab was significantly associated with psoas density
(P¼ 0.04) and visceral fat distance (P¼ 0.022).
Discussion: In an exploratory study of patients with metastatic melanoma being treated with ipilimumab, psoas density and spine-fascia distance
correlated with response and survival. Pre-treatment morphomic analysis, as a correlate of underlying physiology, may help predict response to
immunotherapy.
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INTRODUCTION
Ipilimumab is a monoclonal antibody against cytotoxic T-
lymphocyte-associated antigen-4 (CTLA-4) approved for the treatment
of unresectable or metastatic melanoma. Expressed on activated T-cells,
CLTA-4 binds to B7 molecules on antigen presenting cells and serves to
dampen specific T-cell responses. By blocking CTLA-4 binding, the
negative signal is interrupted, resulting in a more robust T-cell response.
Both extended follow-upof phase II trials anda randomized phase III trial
have established that ipilimumab can induce durable, potentially
curative, tumor regression and improve overall survival [1,2].
As anti-CTLA-4 blockade works non-specifically through the immune
system, as opposed to directly targeting the tumor, there are no tumor-
specific predictive factors that identify patients more or less likely to
respond to therapy. Without this selection process, patients inherently
unlikely to respondmust be exposed tomonths of therapy, and the resultant
toxicity, until the futility is realized. We previously described our
experience with analytic morphomics in patients with stage III melanoma,
demonstrating a strong correlation with survival, even after factoring for
tumor characteristics, suggesting the biology of the host may be as
important as the biology of the tumor [3]. As a surrogate for underlying
physiology, morphomicsmay identify patients less capable of generating a
clinically significant immune response, which may not only be prognostic,
but predictive of response to biologic therapies. To explore this hypothesis,
we performed an exploratory study of analytic morphomics among stage
IV melanoma patients treated with ipilimumab.
METHODS
We conducted an IRB-approved search for patients treated with
ipilimumab for metastatic melanoma at the University of Michigan.We
next identified those patients who had CT scans of the abdomen and
pelvis with IV contrast within a 6 month window of receiving their first
dose of ipilimumab. CT scans were processed using semi-automated
algorithms programmed into MATLAB v13.0 as described in previous
work [4,5]. These algorithms use novel, high-throughput techniques to
identify the linea alba and the anterior abdominal skin along the midline
at each vertebral level from T12 to L4. The average distance between
the linea alba and the anterior skin along T-12 to L4 was labeled the
subcutaneous fat distance (SFD), and the average distance between the
anterior aspect of the vertebra and the linea alba was labeled the visceral
anterior-to posterior (AP) distance (VF). The sum of the SFD and
visceral AP distance was labeled the total AP distance, or total body fat
(TBF).
Both psoas area (PA) and psoas density (PD) were determined in our
study population. Cross-sectional areas of the left and right psoas
muscles at the level of the fourth lumber vertebra (L4) were measured.
The area of the resulting enclosed regions was then computed to
generate the cross-sectional area of the psoas muscles. Fatty infiltration
of the psoas muscle was assessed by measuring the density, in
Hounsfield Units (HU), within these regions, with lower HU reflecting
more fat infiltration [6]. This highly reproducible method correlates
with muscle triglyceride content on muscle biopsy [7–9].
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The data were classified categorically by tabulating the degree of
response, the length of treatment, and individual side effects. Patients
who had interval increase in number or size of lesions following
treatment, deemed progression, were classified as no response; those
who had both progression and regression were classified as mixed
response; those with no change in disease were classified as stable
response; those who had only regression in lesions were classified as
positive response. Each individual side effect was noted in its own
categorical variable, as well as the need for high-dose steroids or the
need for therapy hold. Complication severity was further graded under
mild, intermediate, or severe.
Statistical analysis of the data was done using SAS 9.2 and SPSS 22
software. Patient disease characteristics and the occurrences of toxicity
from ipilimumab were compared using two-sample t- tests or analysis
of variance techniques when the number of groups exceeded two.
Linear regression models were used to assess the association between
continuous covariates. Multivariate models were generated comparing
the relationship between side effects and response. To evaluate the
relationship between morphometric measures, toxicity from
ipilimumab, response to ipilimumab, and overall survival, patients
were stratified into quartiles based on the morphometric measures of
interest. The response rates and occurrences of ipilimumab toxicity in
each quartile were then compared using Fisher’s exact test or chi-square
test when the number of groups exceeded two. For overall survival, time
was calculated from the date of initiation of ipilimumab until disease
recurrence or death, or death, respectively. Patients not experiencing the
endpoint of interest were censored on the date of their last known
clinical follow-up. The Kaplan-Meier method was used to estimate
survival probability in each quartile. Survival in the different quartiles
was compared using the log-rank test. For all statistical tests, P-values at
or below 0.05 were considered significant.
RESULTS
We identified 133 patients treated with ipimilumab for metastatic
melanoma. Among this population, 48 had CT scans of the abdomen
and pelvis with IV contrast, within a 6 month window of receiving their
first dose of ipilimumab that could be processed and programmed into
MATLAB v13.0. Patient and tumor characteristics for both sets of
patients are presented in Table I.
Toxicity
We sought to examine whether toxicity from ipilimumab
correlated with both response and with morphomics. The side
effects of treatment were assessable in 129 patients (2 patients died
before assessment and in 2 patients it was not possible to differentiate
the side effects of treatment versus those of disease burden). The
severity of complications related to ipilimumab treatment was
categorized as none, mild, moderate and severe. Among these 129
patients, 36 (28%) tolerated ipilimumab therapy without complication
while 51 (39%) had only mild complications. Moderate complications
were seen in 24 (17%) patients, and severe complications were seen
in 17 (13%).
TABLE I. Patient and Tumor Characteristics of Study Population
All patients (n¼ 133) Patients with evaluable CT scans (n¼ 48)
Gender
Male 84 (63%) 32 (66%)
Female 49 (37%) 16 (34%)
Age at melanoma diagnosis
Mean (Range) 55.1 (15–90) 56.7 (15–90)
Primary histology
Nodular 29 (22%) 12 (25%)
Superficial Spreading 28 (21%) 8 (16%)
Occult Primary 17 (13%) 7 (14%)
Ocular/Conjunctival 13 (10%) 4 (8%)
Mucosal/Sinonasal 6 (4%) 4 (8%)
Acral lentiginous 6 (4%) 2 (4%)
Other/Unknown 34 (26%) 11 (23%)
Primary Breslow Thickness (mm)
Mean (range) 3.70 (0.35–27) 4.0 (0.7–27)
Primary Nodal Status
Negative 27 (20%) 4 (8%)
Positive 67 (50%) 25 (52%)
Not Staged/Unknown 39 (30%) 19 (40%)
Prior Adjuvant Therapy
None 108 (80%) 35 (72%)
Interferon 15 (11%) 7 (14%)
Clinical Trial 10 (9%) 2 (4%)
Age at stage IV diagnosis
Mean (Range) 58.02 (21–90) 58.97 (31–90)
Time from Initial Diagnosis to Stage IV Disease
Simultaneous 24 (18%) 14 (29%)
< 1 year 24 (18%) 8 (16%)
1–2 years 29 (22%) 5 (10%)
2–3 years 19 (14%) 9 (18%)
3–5 years 14 (10%) 5 (10%)
>5 years 23 (18%) 7 (15%)
1st Line of Stage IV Treatment
Ipilimumab 92 (69%) 32 (66%)
Vemurafenib 8 (6%) 1 (2%)
High-dose IL-2 15 (11%) 9 (18%)
Dasatinib 2 (1%) 0 (0%)
Temozolomide 5 (4%) 2 (4%)
Other clinical trial agent 11 (6%) 4 (8%)
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Response was categorized as none, mixed or partial response, stable
disease or a positive response. Overall, there was a statistically
significant correlation between the presence of complications and
increasing response efficacy (P¼ .0026). There was also a positive
statistical significance between response and complication grade
(P¼ .0168), with response corresponding to severe complications
when controlling for mild and intermediate complications. We were
unable to demonstrate a correlation between any specific toxicity and
outcome.
We examined whether psoas density, BMI and visceral abdominal
girth predicted either the severity of side effects of ipilimumab or were
associated with specific toxicities. The distribution of toxicity (none/
mild/moderate/severe) among the 48 patients with evaluable CT scans
was similar to the entire group, with no complications in 20%, mild in
45%, moderate in 16% and severe complications in 18%. We also
examined specific toxicities including colitis, endocrinopathies,
pruritis, nausea or fatigue. We were unable to demonstrate any
statistically significant correlation between psoas density and the
severity of ipilimumab side effects. There was no association between
colitis, pruritis or nausea and psoas density. Endocrine side effects and
fatigue were both more common among patients with lower psoas
density (4% vs. 13% and 9% vs. 22%, respectively), however these
failed to reach statistical significance. There was no correlation between
BMI and either severity of toxicity or specific side effects.
Response and Outcome
Of the 44 patients had complete analytic morphometry data and
complete outcome data, higher psoas density was associated with
improved response to ipilimumab. Specifically, patients in the highest
quartile of psoas density (patients with the least fatty infiltration of the
psoasmuscle) had a response rate of 36.4%, whichwasmarkedly higher
than the response rate of 9.1% in the remaining patients (P¼ 0.054).
When patients with stable disease were also included in the response
rate, patients in the largest quartile of psoas density had a response rate
of 54.5%, which was significantly higher than the response rate of
18.2% in the remaining patients (P¼ 0.045). Total psoas area,
abdominal girth, and BMI were not significantly correlated with
response to ipilimumab.
We also examined the relationship between morphometric measures
and overall survival from the date of initiation of ipilimumab treatment.
Patients were first stratified into quartiles based on the morphometric
measures of interest. The Kaplan-Meier method was used to estimate
survival probability in each quartile. There was a clear trend towards
improved survival with patients stratified into quartiles based on psoas
density, although this did not reach statistical significance. (P¼ 0.073).
Comparing the top quartile against all other patients, there was a
significantly improved survival compared to all other patients
(P¼ 0.04), as shown in Figure 1. 1-year survival was 71.4% for
patients in the largest quartile of psoas density, compared to 40.1% for
all other patients.
Visceral fat distance was also significantly correlated with survival.
Figure 2 shows survival with patient stratified into quartiles based on
visceral fat distance. Patients in the largest quartile of visceral fat
distance had worse survival compared to all other patients (P¼ 0.022).
1-year survival for patients in the largest quartile of visceral fat distance
was 25.0%, compared to 56.3% for all other patients. Of note, there was
no significant correlation between survival and total psoas area or BMI.
DISCUSSION
The relative benefit of systemic therapies, either in the adjuvant or
metastatic setting, is often assessed by examining prognostic and
predictive factors, the former meant to estimate the potential benefit of
therapy and the latter meant to estimate the likelihood of response. In the
past few years, we have seen the introduction of several new systemic
agents in the treatment of melanoma; small molecule inhibitors for
patients with mutations in the gene encoding BRAF, a key component
of the mitogen-activated protein kinase signaling pathway, and immune
checkpoint regulators. The likelihood of response to targeted therapies
can be predicted by the presence of specific mutations in the BRAF
gene. While a mutation in BRAF is not a guarantee of a positive
Figure 1. Cumulative Survival Stratified by Psoas Density. Patients with the most psoas density (least fatty infiltration) have a significantly better
outcome after treatment with ipilimumab compared with patients with increasing fatty infiltration.
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response to treatment, patients with wild-type B-RAF would not be
expected to respond and are spared the morbidity of treatment.
There have been several attempts to identify biomarkers that may
predict response to immunotherapies. This is particularly important so
that these costly new treatments, which often have severe adverse
reactions, can be targeted to those patients most likely to benefit. To
date, there has been no surrogate or predictive marker for response to
ipilimumab identified [10]. Absolute lymphocyte count (ALC) has been
identified as a potential predictive marker, not just the ALC prior to
therapy, but more importantly the change in ALC after two ipilimumab
treatments [11,12]. Other reported potential markers include c-reactive
protein (CRP), circulating regulatory T-cells (Treg), myeloid derived
suppressor cells (MDSC), CD4þICOShigh T-cells, expression of ICOS,
or antibodies to the cancer testis antigen NY-ESO-1 [10,13–15].
However most of these need to be measured before and during therapy,
meaning patients need to start and maintain therapy, already being
exposed to some cost and potential toxicity, before one can assess
whether they are likely to respond.
Morphomic analysis allows clinicians to map out the three-
dimensional anatomy and density of specific muscles, fat
components and bone. This objective quantification may give a
better assessment of the patients underlying physiology, and relative
frailty, and morphomic analysis has evolved as a superb method for
assessing risk in preoperative patients [4,5]. These morphologic
variations may also predict toxicity and response to systemic
therapy [16,17], and in situations where patient physiology and
tumor biology interact, analytic morphomics may play be a significant
prognostic factor. When examining patients with stage III melanoma,
psoas density, ameasure of the fatty infiltration of the psoasmuscle, was
significantly correlated with survival, even after factoring for age and
known prognostic factors [3]. In renal cell carcinoma, body
composition assessment has also been associated with prognosis [18].
Non-specific immunotherapies, where the patient is not given an
immunologically active agent (such as with the administration of
antibodies or adoptive T-cell therapy), but rather an agent that augments
a pre-existing but clinically insufficient tumor-specific immune
response, is based on the assumption that not only does that response
exist, but can be augmented. It has long been known that aging is
associated with impaired functionality of the immune system, but more
recently, data has emerged linking body composition, nutrition, diet and
frailty with alterations in the adaptive immune response [19,20]. And
while age may be associated with changes in morphomics, there are
multiple factors at play, and physiologic age can be quite different from
chronologic age. For this reason, morphomics may give a better
estimate of underlying functional status than age alone [21]. In the study
of sarcopenia among stage III melanoma patients, when sarcopenia was
included in multivariate analysis, age (long known to be a prognostic
factor in melanoma) was no longer significant [3].
The results of this exploratory study do suggest that among patients
with metastatic melanoma being treated with ipilimumab, both the
response rate and survival were significantly associated with psoas
density. Patients with the least fatty infiltration of the psoasmuscle had a
significantly higher response rate (36.4% versus 9.1%, P¼ .05) and a
longer cumulative survival from the initiation of ipilimumab treatment
(P¼ .04). Another morphometric measurement, spine-fascia distance, a
measure of visceral fat, was also associated with survival. Patients with
the greatest spine-fascia distance had a significantly worse survival
(P¼ .02). There are limitations to this study, in particular the small
number of patients in our cohort who had CT scans of the abdomen and
pelvis performed at the time they started ipilimumab treatment. Patients
staged with PET/CT scans could not be analyzed as the CT scan is non-
contrast and psoas density would not be comparable.
Despite these limitations, the results of this exploratory study are
encouraging. There are several potential advantages to the use of
morphomics in prediction of response to immunotherapy. The
morphomic measurements described (psoas density, spine-fascia
distance) can be obtained with relative ease from any CT scan of the
abdomen and pelvis using oral and intravenous contrast, a test which is
often ordered in the routine evaluation of the patient with stage IV
melanoma. Therefore there would be minimal increased cost. In
addition, as the test is obtained prior to the initiation of therapy, patients
unlikely to response would be spared the cost and toxicity of initiating
treatment before being able to determine the likelihood of success.
These results strongly warrant further study with larger numbers in
Figure 2. Cumulative Survival Stratified by Spine-Fascia Distance. Patients with the highest spine-fascia distance (largest visceral fat distance)
have a significantly worse outcome after treatment with ipilimumab compared with patients with less visceral fat.
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order to perform multivariate analysis, as well as a more objective
delineation of what degree of psoas density (or visceral fat) might
predict poor response to ipilimumab.
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